Calamos Advisors LLC Has $2.56 Million Holdings in CareDx, Inc. (NASDAQ:CDNA)

Calamos Advisors LLC boosted its position in shares of CareDx, Inc. (NASDAQ:CDNA - Free Report) by 65.0% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 143,989 shares of the company's stock after purchasing an additional 56,724 shares during the period. Calamos Advisors LLC owned approximately 0.26% of CareDx worth $2,556,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in CDNA. Principal Financial Group Inc. grew its holdings in CareDx by 6.5% during the 4th quarter. Principal Financial Group Inc. now owns 18,984 shares of the company's stock valued at $406,000 after purchasing an additional 1,151 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in CareDx by 3.9% during the 4th quarter. Bank of New York Mellon Corp now owns 145,270 shares of the company's stock valued at $3,110,000 after purchasing an additional 5,502 shares in the last quarter. US Bancorp DE grew its holdings in CareDx by 907.5% during the 4th quarter. US Bancorp DE now owns 17,168 shares of the company's stock valued at $368,000 after purchasing an additional 15,464 shares in the last quarter. Charles Schwab Investment Management Inc. grew its holdings in CareDx by 2.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 511,922 shares of the company's stock valued at $10,960,000 after purchasing an additional 12,442 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in CareDx during the 4th quarter valued at $3,694,000.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the stock. Wall Street Zen lowered shares of CareDx from a "buy" rating to a "hold" rating in a report on Monday, May 5th. The Goldman Sachs Group decreased their price objective on shares of CareDx from $34.00 to $26.00 and set a "buy" rating for the company in a report on Thursday, April 17th. Stephens reissued an "overweight" rating and set a $40.00 price objective on shares of CareDx in a report on Monday, May 5th. Finally, HC Wainwright reissued a "neutral" rating and set a $25.00 price objective on shares of CareDx in a report on Monday, May 5th. Three analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $30.33.

CareDx Stock Performance

Shares of NASDAQ CDNA traded up $0.42 during midday trading on Tuesday, hitting $18.87. The company's stock had a trading volume of 149,617 shares, compared to its average volume of 916,517. CareDx, Inc. has a 1-year low of $14.09 and a 1-year high of $34.84. The firm's fifty day moving average price is $17.79 and its 200-day moving average price is $19.71. The firm has a market cap of $1.05 billion, a P/E ratio of 16.41 and a beta of 2.19.

CareDx (NASDAQ:CDNA - Get Free Report) last posted its quarterly earnings results on Wednesday, April 30th. The company reported $0.09 EPS for the quarter, beating the consensus estimate of $0.06 by $0.03. The business had revenue of $84.69 million during the quarter, compared to analyst estimates of $84.56 million. CareDx had a net margin of 19.79% and a return on equity of 21.16%. The company's quarterly revenue was up 17.6% on a year-over-year basis. During the same period in the previous year, the business posted ($0.03) EPS. As a group, research analysts predict that CareDx, Inc. will post -0.9 earnings per share for the current fiscal year.

Insider Activity

In related news, Director William A. Hagstrom sold 19,391 shares of CareDx stock in a transaction dated Wednesday, June 11th. The shares were sold at an average price of $19.90, for a total value of $385,880.90. Following the sale, the director directly owned 53,979 shares in the company, valued at $1,074,182.10. This trade represents a 26.43% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Hannah Valantine sold 10,570 shares of the business's stock in a transaction dated Wednesday, June 18th. The stock was sold at an average price of $19.16, for a total transaction of $202,521.20. Following the sale, the director owned 38,994 shares in the company, valued at $747,125.04. This trade represents a 21.33% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 129,078 shares of company stock valued at $2,234,115. 4.40% of the stock is owned by company insiders.

CareDx Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.